# MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.

Type: Company

Source: GetYourBrief — https://getyourbrief.com/entity/mirae-asset-global-etfs-holdings-ltd
Canonical HTML page: https://getyourbrief.com/entity/mirae-asset-global-etfs-holdings-ltd

## Timeline

- **2026-07-22**: Quarterly earnings released — SMBC reports EPS of $1.83 vs. $1.52 estimate, revenue of $51.77M.
- **2026-06-26**: Piper Sandler adjusts PT — Piper Sandler reiterates Neutral, boosts target from $71 to $79.
- **2026-06-05**: Insider sale by EVP Windes — EVP Richard Windes sells 2,000 shares at average $69.70, totaling $139,400.
- **2026-06-04**: Weiss Ratings reiterates Buy — Weiss Ratings issues a 'buy (b)' rating on SMBC.
- **2026-04-24**: Stephens bullish call — Stephens reiterates Overweight rating, lifts PT to $76 from $72.
- **2026-04-09**: KBW target price increase — Keefe, Bruyette & Woods raises price target from $64 to $65, maintaining Market Perform rating.

## Recent coverage (5 stories, network-wide)

### Globant Misses EPS by $0.10; Revenue $614.4M, Stock Falls 8.9%
2026-08-16 11:39:33 · Sector: finance · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Globant reported EPS of $1.40, missing consensus by $0.10, while revenue of $614.42 million slightly beat estimates but was flat year over year. Shares fell 8.9% to $37.35 as analysts lowered price targets. The company reiterated FY2026 EPS guidance of $5.75-$6.15 and Q3 guidance of $1.43.
Full story: https://getfinancebrief.com/story/globant-q2-2026-earnings-miss-finance

### Collegium Pharma EPS Beats by $0.20; Revenue Grows 6.3% to $199.88M
2026-08-09 18:29:04 · Sector: health · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Collegium Pharmaceutical's Q2 2026 earnings beat signals sustained demand for its abuse-deterrent pain medications. Revenue grew 6.3% to $199.88M, and EPS of $1.92 surpassed forecasts by $0.20, indicating commercial strength despite regulatory pressures.
Full story: https://gethealthbrief.com/story/collegium-pharma-q2-2026-earnings-health

### COLL Beats Q2 EPS by $0.20, Stock Gains 1.24% to $29.47
2026-08-09 18:28:55 · Sector: finance · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Collegium Pharmaceutical delivered an 11.6% EPS beat and modest revenue beat, lifting shares to $29.47. High ROE and institutional accumulation offset by high leverage and mixed analyst ratings create a nuanced investment case.
Full story: https://getfinancebrief.com/story/collegium-pharma-q2-2026-earnings-finance

### COLL Q2 EPS Beats by $0.20; Revenue Up 6.3% to $199.88M
2026-08-09 18:28:47 · Sector: bio · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Collegium Pharmaceutical's earnings beat of $0.20 per share, reaching $1.92 on $199.88M revenue, highlights its commercial success in the abuse-deterrent opioid space, a key sector for the biopharma industry.
Full story: https://getbiobrief.com/story/collegium-pharma-q2-2026-earnings-bio

### SMBC Beats EPS by $0.31, Stock Down 1.4% Amid Insider Selling
2026-07-23 00:54:41 · Sector: finance · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Southern Missouri Bancorp delivered a strong quarter with earnings of $1.83 per share, beating estimates by $0.31 on revenue of $51.77 million. However, the stock fell 1.4% to $75.41 as analysts remain divided and insider selling raises questions.
Full story: https://getfinancebrief.com/story/smbc-earnings-beat-stock-down-insider-sell

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getyourbrief.com/guides/methodology for the full editorial methodology.